Jun 16, 2025
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Jun 04, 2025
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
May 28, 2025
Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi
Mar 11, 2025
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
Jan 08, 2025
Halia Therapeutics to Attend the 43rd J.P. Morgan Healthcare Conference and Present at BioPharma Obesity Innovation Forum in San Francisco
Jan 06, 2025
Halia Therapeutics Strengthens Leadership and Clinical Operations Team
Dec 10, 2024
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
Dec 05, 2024
Halia CEO David Bearss, Ph.D., to Present and Participate in Panel Discussion at Obesity Innovation Therapeutics Summit 2024
Oct 31, 2024
Halia Therapeutics to Present Promising Data at Obesity Week 2024: HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination
Oct 21, 2024
Halia Therapeutics to Attend Global Health Exhibition 2024
Oct 14, 2024
Halia Therapeutics to Participate in Panel at BIO Investor Forum 2024
Oct 08, 2024
PharmaVoice Recognizes Halia Therapeutics CEO David Bearss as One of the 100 Standout Leaders in the Life Sciences Industry
Oct 07, 2024
Halia Therapeutics Announces First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer's Disease
Sep 23, 2024
Halia Therapeutics Reveals Promising Preclinical Obesity Data: HT-6184 and Semaglutide Combination Enhances Weight Loss and Preserves Lean Muscle Mass
Aug 06, 2024
Halia Therapeutics' CEO, Dr. David J. Bearss, to Present Groundbreaking Research on Chronic Inflammation and Aging at the 3rd Edition Global Longevity Federation
May 29, 2024
Halia Therapeutics to Participate at BIO International Convention and The European Hematology Association Hybrid Congress
May 14, 2024
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer's Disease at Discovery Europe 2024
Apr 17, 2024
Halia Therapeutics to Present at Asia BIO 2024
Mar 12, 2024
Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference
Feb 21, 2024
Halia Therapeutics to Present at 2024 BIO CEO & Investor Conference